The promotion and reimbursement practices for the medtech company’s implantable CPAP alternative are under scrutiny.

An implant for sleep apnea is one of the few CPAP alternatives. This article compares hypoglossal nerve stimulation and ...

During its fourth-quarter earnings call this week, Inspire Medical disclosed that it has become the subject of a civil probe ...

CEO Tim Herbert told investors the company received a civil investigative demand from the Department of Justice in January ...

Inspire Medical shares dipped — but have since mostly recovered — following news of a government investigation following Q4 ...

Inspire Medical Systems (NYSE:INSP), known for its innovative devices that use neurostimulation to treat sleep apnea, ...

Inspire Medical Systems is a leader in neurostimulation technology for obstructive sleep apnea; its devices are the only ones of their type with FDA approval. The company is now focused on ...

Inspire expects full-year earnings to be $2.10 to $2.20 per share, with revenue in the range of $940 million to $955 million. This story was generated by Automated Insights ( ...

Inspire makes mask-free implants to treat obstructive sleep apnea. The implants deliver pulses ... The company plans a full launch of its Inspire V device in 2025 after receiving Food and Drug ...

Inspire (INSP) delivered earnings and revenue surprises of 55.41% and 0.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?